TCMP
GSK icon

Thrive Capital Management (Pennsylvania)’s GSK GSK Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,905
Closed -$296K – 194
2024
Q1 		$296K Buy
6,905
+400
+6% +$16.5K 0.16% 81
2023
Q4 		$241K Buy
+6,505
New +$234K 0.13% 125
2021
Q2 		– Sell
-20,618
Closed -$920K – 112
2021
Q1 		$920K Buy
20,618
+10,371
+101% +$471K 0.86% 33
2020
Q4 		$471K Buy
+10,247
New +$471K 0.5% 47

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s GSK Position: Q2 2024 in Review

Thrive Capital Management (Pennsylvania) sold out of GSK (GSK) in Q2 2024, closing a stake of 6,905 shares — an estimated $296K sold.

Thrive Capital Management (Pennsylvania) first reported a position in GSK in Q4 2020 and held it in 4 quarters. The position peaked at $920K in Q1 2021. 885 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • Thrive Capital Management (Pennsylvania) reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
  • Thrive Capital Management (Pennsylvania) sold 6,905 GSK shares in Q2 2024, an estimated $296K.
  • Thrive Capital Management (Pennsylvania) first reported a position in GSK in Q4 2020 and held it in 4 quarters.
  • Thrive Capital Management (Pennsylvania)'s GSK position peaked at $920K in Q1 2021.
  • 885 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2024, filed 9 Aug 2024.